SecBot SecBot
SECBOTREPLAY Home › Report › ABT

ABT · Rothschild & Co double-upgraded ABT (ABBOTT LABORATORIES) from Neutral…

ABBOTT LABORATORIES · ANALYST-UPGRADE filed Oct 2, 2026 at 05:52 ET

At the news

MIXEDIMPACT 3/10

ANALYST-UPGRADE filed Oct 2, 2026 at 05:52 ET

Rothschild & Co double-upgraded ABT (ABBOTT LABORATORIES) from Neutral to Buy on October 2, 2026, raising the price target to $127 from $119. The new target implies 31.3% upside from the current price of $96.69. Rothschild & Co has a 54% accuracy rate on 52 scored calls with an average return of 2.9%. The consensus on ABT is heavily bullish: 25 analysts cover the stock, with 12 Strong Buy, 13 Buy, and 8 Hold ratings, zero Sell or Strong Sell. The mean price target is $120.26, median $120, with a high of $135 and low of $103. Rothschild's $127 target sits above the mean and median, reflecting an above-consensus bullish view. Over the past 30 days, ABT has seen 2 upgrades and 0 downgrades, while EPS revisions for the current quarter show 7 upward and 10 downward revisions, a mixed near-term signal. Insider selling has been significant, including a $25.3M sale by Ford Robert B on August 25, 2026, and institutional trimming by major funds including JPMorgan (-43.6%) and Capital Research (-25.8%). The double upgrade from a mid-accuracy firm with a target above consensus is a notable bullish catalyst, but heavy insider and institutional selling creates a conflicting signal. The bottom line: Rothschild's contrarian double upgrade adds momentum to an already bullish consensus, but the heavy insider and institutional selling warrants caution.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access